Literature DB >> 28058507

ALS/FTLD: experimental models and reality.

Rachel H Tan1,2,3, Yazi D Ke4, Lars M Ittner5,6, Glenda M Halliday7,8,9.   

Abstract

Amyotrophic lateral sclerosis is characterised by a loss of upper and lower motor neurons and characteristic muscle weakness and wasting, the most common form being sporadic disease with neuronal inclusions containing the tar DNA-binding protein 43 (TDP-43). Frontotemporal lobar degeneration is characterised by atrophy of the frontal and/or temporal lobes, the most common clinical form being the behavioural variant, in which neuronal inclusions containing either TDP-43 or 3-repeat tau are most prevalent. Although the genetic mutations associated with these diseases have allowed various experimental models to be developed, the initial genetic forms identified remain the most common models employed to date. It is now known that these first models faithfully recapitulate only some aspects of these diseases and do not represent the majority of cases or the most common overlapping pathologies. Newer models targeting the main molecular pathologies are still rare and in some instances, lack significant aspects of the molecular pathology. However, these diseases are complex and multigenic, indicating that experimental models may need to be targeted to different disease aspects. This would allow information to be gleaned from a variety of different yet relevant models, each of which has the capacity to capture a certain aspect of the disease, and together will enable a more complete understanding of these complex and multi-layered diseases.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; C9orf72; Frontotemporal lobar degeneration; Microtubule associated protein tau; Superoxide dismutase 1; tar DNA-binding protein 43

Mesh:

Year:  2017        PMID: 28058507     DOI: 10.1007/s00401-016-1666-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  29 in total

1.  Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients.

Authors:  Claire H Stevens; Natalie J Guthrie; Marloes van Roijen; Glenda M Halliday; Lezanne Ooi
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-01       Impact factor: 3.685

Review 2.  Emerging roles of extracellular vesicles in neurodegenerative disorders.

Authors:  Yang You; Tsuneya Ikezu
Journal:  Neurobiol Dis       Date:  2019-06-20       Impact factor: 5.996

Review 3.  Phenotypic Suppression of ALS/FTD-Associated Neurodegeneration Highlights Mechanisms of Dysfunction.

Authors:  Mathieu Bartoletti; Daryl A Bosco; Sandrine Da Cruz; Clotilde Lagier-Tourenne; Nicole Liachko; Sebastian Markmiller; Kristin M Webster; Kristi A Wharton
Journal:  J Neurosci       Date:  2019-10-16       Impact factor: 6.167

4.  Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination.

Authors:  Jia Wang; Wan Yun Ho; Kenneth Lim; Jia Feng; Greg Tucker-Kellogg; Klaus-Armin Nave; Shuo-Chien Ling
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-29       Impact factor: 11.205

Review 5.  Tau tubulin kinases in proteinopathy.

Authors:  Laura M Taylor; Pamela J McMillan; Brian C Kraemer; Nicole F Liachko
Journal:  FEBS J       Date:  2019-05-22       Impact factor: 5.542

Review 6.  Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers.

Authors:  Michael Tran Duong; David A Wolk
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-03       Impact factor: 6.030

7.  Sexually dimorphic RNA helicases DDX3X and DDX3Y differentially regulate RNA metabolism through phase separation.

Authors:  Hui Shen; Amber Yanas; Michael C Owens; Celia Zhang; Clark Fritsch; Charlotte M Fare; Katie E Copley; James Shorter; Yale E Goldman; Kathy Fange Liu
Journal:  Mol Cell       Date:  2022-05-18       Impact factor: 19.328

8.  Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction.

Authors:  Audrey Yi Tyan Peng; Ira Agrawal; Wan Yun Ho; Yi-Chun Yen; Ashley J Pinter; Jerry Liu; Qi Xuan Cheryl Phua; Katrianne Bethia Koh; Jer-Cherng Chang; Emma Sanford; Jodie Hon Kiu Man; Peiyan Wong; David H Gutmann; Greg Tucker-Kellogg; Shuo-Chien Ling
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-30       Impact factor: 11.205

9.  The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice.

Authors:  Diane Ly; Anjila Dongol; Peter Cuthbertson; Thomas V Guy; Nicholas J Geraghty; Reece A Sophocleous; Lucia Sin; Bradley J Turner; Debbie Watson; Justin J Yerbury; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

Review 10.  Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jessica Root; Paola Merino; Austin Nuckols; Michelle Johnson; Thomas Kukar
Journal:  Neurobiol Dis       Date:  2021-03-31       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.